

ASX Announcement

23 May 2024

OncoSil signs distribution agreement for Saudi Arabia

Distribution agreement with Abdulla Fouad Group company creates runway for OncoSil™ device to penetrate the largest market in the Middle East

Key Highlights

- ✓ OncoSil Medical signs an exclusive 3-year distribution agreement with Saudi Arabia-based company Abdulla Fouad for Medical Supplies and Services (AFMS)
- ✓ The agreement will see AFMS market the OncoSil™ device in the Kingdom of Saudi Arabia
- ✓ Saudi Arabia, the largest country in the Middle East, possesses a large and growing healthcare sector with first class infrastructure
- ✓ OncoSil expects to launch the OncoSil™ device in the Kingdom of Saudi Arabia once the required local registration process is completed.

Sydney, Australia – 23 May 2024: Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) is pleased to announce the signing of an exclusive 3-year distribution agreement with Saudi Arabia-based company Abdulla Fouad for Medical Supplies and Services (AFMS).

Under the agreement, AFMS will market the OncoSil™ device in the Kingdom of Saudi Arabia, which has a large and growing healthcare sector along with quality healthcare infrastructure.

Saudi distribution agreement a key deliverable in plans to penetrate Middle East markets

OncoSil has signed an exclusive 3-year distribution agreement with Saudi Arabia-based company AFMS. Under the agreement, AFMS will market the OncoSil™ device in the Kingdom of Saudi Arabia, the largest country in the Middle East region.

This highly significant agreement is a critical step in OncoSil’s plans to penetrate the Saudi Arabian healthcare sector, which is growing, and has excellent infrastructure.

OncoSil expects to launch the OncoSil™ device in the Kingdom of Saudi Arabia once the required local registration process is completed.

AFMS is a leading Saudi healthcare company

AFMS is a highly regarded medical/healthcare company that is part of dynamic Saudia Arabia-based conglomerate, the Abdulla Fouad Group (AFG) of companies.

Since its establishment in 1983, AFMS has been at the forefront of Saudi Arabia’s healthcare vendors, assisting the Kingdom in providing the best healthcare solutions to its citizens. The company’s team of high-calibre professionals, together with its wide-ranging operational infrastructure, has facilitated the sourcing, acquisition, and distribution of high-quality medical supplies and equipment in the Kingdom, with the OncoSil™ device now added to this list.

OncoSil Medical CEO & Managing Director Nigel Lange, said: *“We are excited by the signing of this agreement with highly regarded Saudi Arabia-based Abdulla Fouad for Medical Supplies and Services, which opens the way for the OncoSil™ device to enter another highly significant target market. It represents a key deliverable in our plans to penetrate the Middle East market, with Saudi Arabia boasting a large and growing healthcare sector as well as impressive healthcare-related infrastructure. We now look forward to launching the OncoSil™ device in Saudi Arabia once the required local registration process is completed.”*

Abdulla Fouad for Medical Supplies and Services General Manager Asem Manasra, said: *“We are thrilled to sign this distribution agreement with OncoSil Medical, which continues to effectively validate the effectiveness of its unique medical technology. From our perspective, the agreement demonstrates the continued commitment by our entire team to deliver ongoing improvements to patient health care and safety to the population of the Kingdom of Saudi Arabia by giving them access to cutting edge diversified products and solutions like the OncoSil™ device.”*

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

<p>Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 16096424981</p>	<p>Mr. Christian Dal Cin CFO & Company Secretary E: c.dalcin@acclime.com T: +61 3 9824 5254</p>	<p>Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699</p>
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (³²P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

References: 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>

About Abdulla Fouad for Medical Supplies & Services

Medical/healthcare company Abdulla Fouad for Medical Supplies & Services (AFMS) is part of dynamic Saudia Arabia-based conglomerate, the Abdulla Fouad Group (AFG) of companies, which services the oil & gas, energy, healthcare, information technology, consumer, and construction sectors.

Since its establishment in 1983, AFMS has been at the forefront of Saudi Arabia's healthcare vendors, assisting the Kingdom in providing the best healthcare solutions to its citizens. The company's team of high-calibre professionals, together with its wide-ranging operations infrastructure, has enabled it to gain exclusive regional representation for a wide range of international manufacturers and suppliers, in the process continuously adding to its impressive list of partners and clients.